US Stock MarketDetailed Quotes

SOPH Sophia Genetics

Watchlist
  • 3.640
  • +0.060+1.68%
Close Nov 1 16:00 ET
  • 3.640
  • 0.0000.00%
Post 20:02 ET
241.00MMarket Cap-3568P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

Comments

    $Sophia Genetics (SOPH.US)$
    SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
    SOPHiA GENETICS (Nasdaq: SOPH) will present groundbreaking research at ESMO 2024, showcasing AI-driven patient stratification for non-small cell lung cancer (NSCLC) treatment.
    The study, conducted with AstraZeneca, analyzed the POSEIDON Phase 3 clinical trial using multimodal machine learningto identify NSCLC patient subgroups most likely to benefit...
    $Sophia Genetics (SOPH.US)$
    SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
    SOPHiA GENETICS (Nasdaq: SOPH) announced updates on SOPHiA UNITY, its global consortium for precision oncology research, at ESMO 2024. Several world-renowned healthcare organizations have joined the initiative, including Exactis Innovation in Canada, Institut Paoli-Calmettes in France, and potentially Gemelli Hospital in Italy. These institutions join inaugural member Memorial Sloan Kettering Cancer Cen...
    $Sophia Genetics (SOPH.US)$
    SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities
    SOPHiA GENETICS (Nasdaq: SOPH) announced a collaboration with Microsoft and NVIDIA to launch a whole genome sequencing (WGS) analytical solution by end of 2024. The new WGS application aims to deliver fully analyzed genome insights within the same day, enhancing research, drug discovery, and clinical care. Leveraging Microsoft Azure and NVIDIA Parabricks, the solution will provide scalable and rapid...
    $Sophia Genetics (SOPH.US)$
    NEWS
    SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
    Unilabs, a leading diagnostic provider in Europe, has implemented SOPHiA GENETICS' AI technology for HRD testing in solid tumors across its network in Switzerland. HRD, a common alteration in ovarian cancer, affects approximately half of newly diagnosed patients, making it a important factor in treatment planning. SOPHiA GENETICS' SOPHiA DDM™ Platform u...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data